Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.14|
|52 Week High||US$0.85|
|52 Week Low||US$4.99|
|1 Month Change||3.64%|
|3 Month Change||-10.24%|
|1 Year Change||18.80%|
|3 Year Change||-57.93%|
|5 Year Change||-67.43%|
|Change since IPO||-78.29%|
Recent News & Updates
|TYME||US Biotechs||US Market|
Return vs Industry: TYME underperformed the US Biotechs industry which returned 26% over the past year.
Return vs Market: TYME underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: TYME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: TYME's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.
Tyme Technologies Fundamentals Summary
|TYME fundamental statistics|
Is TYME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TYME income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.15|
|Net Profit Margin||0.00%|
How did TYME perform over the long term?See historical performance and comparison
Is Tyme Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TYME's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TYME's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TYME is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TYME is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TYME's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TYME is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.3x).
How is Tyme Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tyme Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Tyme Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TYME is currently unprofitable.
Growing Profit Margin: TYME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: TYME has a negative Return on Equity (-27.03%), as it is currently unprofitable.
How is Tyme Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: TYME's short term assets ($74.7M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: TYME's short term assets ($74.7M) exceed its long term liabilities ($2.0M).
Debt to Equity History and Analysis
Debt Level: TYME is debt free.
Reducing Debt: TYME has no debt compared to 5 years ago when its debt to equity ratio was 6.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TYME has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TYME has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 25.8% each year.
What is Tyme Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TYME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TYME's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TYME's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richie Cunningham (50 yo)
Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 24, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...
CEO Compensation Analysis
Compensation vs Market: Richie's total compensation ($USD1.85M) is above average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Insufficient data to compare Richie's compensation with company performance.
Experienced Management: TYME's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: TYME's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TYME insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.7%.
Tyme Technologies, Inc.'s employee growth, exchange listings and data sources
- Name: Tyme Technologies, Inc.
- Ticker: TYME
- Exchange: NasdaqCM
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$196.316m
- Shares outstanding: 172.21m
- Website: https://www.tymeinc.com
Number of Employees
- Tyme Technologies, Inc.
- 1 Pluckemin Way
- Suite 103
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 23:07|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.